[Pubmed] Clinicopathological profile and treatment outcomes of advanced/unresectable thymic malignancies from a tertiary
-
RSS-Bot
Auteur du sujet - Ami(e) de Diamant

- Messages : 6500
- Enregistré le : 31 mai 2020 09:57
- 6
- Zodiaque :
- Âge : 22
- Contact :
[Pubmed] Clinicopathological profile and treatment outcomes of advanced/unresectable thymic malignancies from a tertiary
Curr Probl Cancer. 2026 Aug 7;64:101330. doi: 10.1016/j.currproblcancer.2026.101330. Online ahead of print.
ABSTRACT
BACKGROUND: Thymomas, though rare, are the most common anterior mediastinal neoplasms in adults, with incidence of 0.13 per 100,000 person-years. Due to indolent nature and lack of randomized trials, treatment relies on retrospective data. Literature on outcomes of unresectable thymomas in India is limited.
METHODS: This retrospective study was conducted at a tertiary cancer centre in north India, analysing records of patients with advanced/unresectable thymic malignancies (stage III-IV) treated between January 2012 and December 2023. Clinicopathological features, response rates, progression-free survival (PFS), and overall survival (OS) were assessed.
RESULTS: A total of 43 patients (median age 40 years [range 22-72]; 76.7% male) were included. Histology revealed thymoma in 36 (83.7%), thymic carcinoma in 4 (9.3%), and thymic neuroendocrine tumours in 3 (7%). Common symptoms were cough (60.5%), dyspnoea (60.5%), and chest pain (55.8%). Stage distribution was - III (20.9%), IVA (46.5%), and IVB (32.6%). Liver (14%) was the most common site of distant metastasis. Myasthenia gravis and pure red cell aplasia occurred in 7% each. Forty (93%) patients received systemic therapy, primarily Cyclophosphamide-Adriamycin-Cisplatin (75%). The objective response rate for first-line systemic therapy was 37.5% (all partial responses) with a clinical benefit rate of 87.5%. Twelve (30%) underwent surgery, with R0 resection in 6 (15%). Median PFS was 16.4 months, and OS was 56 months.
CONCLUSION: Systemic therapy and surgery in selected cases provide meaningful outcomes in unresectable thymomas, emphasizing the need for prospective studies to refine treatment strategies.
PMID:42567081 | DOI:10.1016/j.currproblcancer.2026.101330
Source: https://pubmed.ncbi.nlm.nih.gov/4256708 ... 8&v=2.20.1
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page

Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]
Bonne lecture...
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page

Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]
Bonne lecture...





